3SBio Inc. — Capital/Financing Update 2018

Jan 15, 2018

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or on reliance upon the whole or any part of the contents of this announcement.

==> picture [110 x 133] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT

3SBio Inc. (the “ Company ”) wishes to provide to the shareholders of the Company the attached joint press release in respect of an exclusive licensing agreement entered into between Hongkong Sansheng Medical Limited (“ Hongkong Sansheng ”, a wholly-owned subsidiary of the Company) and Toray Industries, Inc., for the development and commercialization of certain oral disintegration tablet formulation of antipruritic drug TRK-820 (also known as “REMITCH®” as approved in Japan) in the People’s Republic of China (not including Hong Kong, Macau and Taiwan) by Hongkong Sansheng.

This is a voluntary announcement made by the Company. Shareholders of the Company and potential investors are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board 3SBio Inc. Dr. LOU Jing Chairman

Shanghai, the PRC 15 January 2018

As at the date of this announcement, the directors of the Company are Dr. LOU Jing, Mr. TAN Bo, Ms. SU Dongmei and Mr. HUANG Bin as executive directors; Mr. LIU Dong and Mr. WANG Steven Dasong as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Mr. MA Jun as independent non-executive directors.

1

==> picture [92 x 29] intentionally omitted <==

==> picture [87 x 29] intentionally omitted <==

TORAY AND 3SBIO REACH EXCLUSIVE CHINESE LICENSE AGREEMENT ON ANTIPURITIC AGENT, TRK-820

January 15, 2018 — Toray Industries, Inc. (head office: Chuo-ku, Tokyo; President Akihiro Nikkaku; hereinafter referred to as “ Toray ”) and 3SBio Inc. (head office: Shenyang; Chairman & CEO: Jing Lou: hereinafter referred to as “ 3SBio ”) announced that Toray and 3SBio’s whollyowned subsidiary, Hongkong Sansheng Medical Limited (“ Hongkong Sansheng ”), entered into an exclusive licensing agreement on certain oral disintegration tablet formulation of antipruritic drug TRK-820 (Toray development code; generic name: nalfurafine hydrochloride; also known as “REMITCH®” as approved in Japan) that is developed and manufactured by Toray (the “ Product ”). Pursuant to the Agreement, Toray agreed to grant Hongkong Sansheng the exclusive right to develop and commercialize the Product in the People’s Republic of China (not including Hong Kong, Macau and Taiwan). Hongkong Sansheng agreed to pay initial payment and milestone payments to Toray.

About TRK-820

TRK-820 is a highly selectiveк(kappa)-opioid receptor agonist developed by Toray. The soft capsule dosage-form of the TRK-820 has been sold as in Japan since 2009 to treat hemodialysisrelated uremic pruritus (used only when sufficient efficacy is not obtained with the existing therapies or treatments). Additional indications of TRK-820, pruritus in chronic liver disease patients and pruritus in peritoneal dialysis patients were approved in Japan in 2015 and 2017, respectively. In addition, oral disintegration tablet was approved and launched in Japan in 2017. The oral disintegration tablet can be taken with or without water. Therefore it is convenient for patients whose swallowing capabilities have deteriorated or those who have restrictions on water intake, and is expected to lead to improved drug intake compliance.

About Pruritus in Dialysis Patients

Pruritus experienced by hemodialysis patients, though non-inflammatory, is generalized and severe. Also, histamine, a generally known substance for causing itching, is known to have less involvement with the itching, and therefore, conventional antipruritic agents including antihistamines cannot fully suppress this itching in many cases. According to the article entitled “ Progress in the pathogenesis and treatment of uremic pruritus ” in Chinese Journal of Kidney Disease Investigation (Electronic Edition) (2014 (3):143–146), Uremic pruritus (UP) is the most common skin complication in patients with end-stage renal disease, which occurs in 15%~49% of pre dialysis patients, and 50%~90% of hemodialysis and peritoneal dialysis patients. From the results of Dialysis Outcomes and Practice Patterns Study (DOPPS), about 42% of dialysis patients were disturbed by moderate to severe cutaneous pruritus, which not only seriously affected the quality of life of patients, but also some patients even experienced anxiety, depression and sleep disorders. Toray and 3SBio hope to make contributions to relieve the pruritus of dialysis patients in China through this alliance.

2

Toray Industries, Inc.

Head office: 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo President: Akihiro Nikkaku Website: http://www.toray.com/

Toray Industries, Inc. was established in 1926 as a manufacturer of chemical fiber rayon. Subsequently, it developed various advanced materials such as synthetic fibers, resins, films, carbon fibers, high-performance water treatment membranes, pharmaceuticals and medical supplies and developed and further cultivates the markets. In April 2011, it drafted and implemented the longterm corporate vision AP-Growth TORAY 2020 as a unified policy of its corporate activities in pursuit of becoming “a corporate group that continually increases revenues and profits”. As its third stage, in 2017, Toray embarked on the medium-term management program “Project AP-G2019” with focus on “expansion of businesses in growth business fields and regions”. The Toray Group currently has operations in 26 countries and regions all over the world, including Japan. In addition, the life science field is part of the Intensively Developing and Expanding Businesses, which are the next-generation growth engine under “Project AP-G2019”, and the Toray Group aims for further growth in the business field. Under the corporate philosophy of contributing to society through the creation of new value with innovative ideas, technologies and products and corporate slogan of “Innovation by Chemistry”, it is driven by the unwavering aspiration to become a global top company of advanced materials and take on the challenge of innovation (innovation and creation) in every corporate and business activity field.

3SBio Inc.

Head office: No.3 A1, Road 10 Shenyang Economy & Technology Development Zone, Shenyang President: Jing Lou Website: http://www.3sbio.com/

3SBio is a fully-integrated biotechnology company in China with market-leading biopharmaceutical franchises in oncology, auto-immune diseases and nephrology. 3SBio has TPIAO, the only commercialized recombinant human thrombopoietin (“ rhTPO ”) product in the world; Yisaipu, the first-to-market recombinant human tumor necrosis factor-α receptor II (TNFR) – IgG Fc fusion protein for the treatment of rheumatoid arthritis; and EPIAO and SEPO, recombinant human erythropoietin (“ rhEPO ”) products. 3SBio has also licensed the China commercial rights to AstraZeneca’s Byetta/Bydureon and Eli Lilly’s Humulin. 3SBio is focused on building an innovative product pipeline, with over 16 National Class 1 candidates under development. 3SBio’s manufacturing capabilities include recombinant proteins, monoclonal antibodies and chemically synthesized molecules, with production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Como, Italy. 3SBio is actively pursuing international expansion through acquisition, licensing and partnerships.

3